Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.
about
Molecular basis for passive immunotherapy of Alzheimer's diseaseAffinity improvement of a therapeutic antibody to methamphetamine and amphetamine through structure-based antibody engineeringImproving antibody affinity by mimicking somatic hypermutation in vitro.Use of a peptide mimotope to guide the humanization of MRK-16, an anti-P-glycoprotein monoclonal antibody.Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity.A general method for greatly improving the affinity of antibodies by using combinatorial librariesDesign of synthetic antibody libraries.Angiogenesis in urological malignancy: prognostic indicator and therapeutic target.Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.Spatially addressed combinatorial protein libraries for recombinant antibody discovery and optimization.Beyond natural antibodies: the power of in vitro display technologies.Integrin alpha(v)beta(3)-Targeted Cancer Therapy.Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases.An efficient method for variable region assembly in the construction of scFv phage display libraries using independent strand amplification.Affinity maturation of antiHER2 monoclonal antibody MIL5 using an epitope-specific synthetic phage library by computational design.General aspects of anti-angiogenesis and cancer therapy.Affinity maturation and fine functional mapping of an antibody fragment against a novel neutralizing epitope on human vascular endothelial growth factor.Development of a 'mouse and human cross-reactive' affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy.Effective Optimization of Antibody Affinity by Phage Display Integrated with High-Throughput DNA Synthesis and Sequencing TechnologiesDrugs to suppress cough.Synthesis, characterization, and biological evaluation of integrin alphavbeta3-targeted PAMAM dendrimers.Specific targeting of human integrin α(v)β (3) with (111)In-labeled Abegrin™ in nude mouse models.Antibody engineering toward high-sensitivity high-throughput immunosensing of small molecules.Monoclonal antibodies: technologies for early discovery and engineering.A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor.Differential regulation of monocyte cytokine release by αV and β(2) integrins that bind CD23.Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A.Deep Sequencing-guided Design of a High Affinity Dual Specificity Antibody to Target Two Angiogenic Factors in Neovascular Age-related Macular Degeneration.Expression of antisense to integrin subunit beta 3 inhibits microvascular endothelial cell capillary tube formation in fibrin.Fitness loss and library size determination in saturation mutagenesisInhibition of angiogenesis in vitro by alphav integrin-directed antisense oligonucleotides.The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human αVβ3 Integrin via Steric Hindrance.Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).
P2860
Q27648521-6D5719AB-4FCD-4731-A3A2-01DC27EF469BQ27681289-C136CE64-56B0-4781-88BB-EF260708D7D0Q30724948-4DC6D64B-D478-40DB-9EE2-E547A907AFCEQ30773361-9EEAD30D-3D6E-46A2-AF2A-2A41D80266B4Q30923970-8892BDE5-CD04-4401-A4A2-E7E866FC385AQ33216580-DDD0D217-FE1A-4BC4-B935-DE95E16992D4Q33283622-263D5C83-DA9F-437B-BAB8-1B27B2E01C9DQ33598141-E9BF6803-968F-4BEA-811E-93515AC994AAQ33687487-F30B95DE-9296-4945-AB68-6D8238943E2AQ33726840-E5476118-7490-4BC7-870C-42A62A1FB215Q33841864-7127B9BB-E18F-4858-9C31-119F4CE681D7Q33983773-B7B73CE8-EDCF-4B9B-9866-4354CC104325Q34154425-3C02D712-E914-49A5-8C40-E60BC011C6BFQ34301659-CAE76976-E0DE-4B1B-A680-84B6921E6525Q34419541-B8909C60-B6B6-4A5D-A6ED-0500BC8621E4Q34452066-C38ACBF5-ACC2-4254-A149-D8031086443CQ34736631-12D2CB3B-6447-4505-853C-B904754170A2Q35158112-86F83C23-C07D-45D3-AE45-A6C12D9C680EQ35654123-74AC2D85-DDA6-4148-975D-E4F942F1CB97Q36040853-AB667AA6-3E1F-4B1B-BBEE-7776BC619748Q36952077-5037B36B-83A4-478D-869C-56BA78C12C88Q37592073-E62A626D-D05C-443A-BA5B-ACC5E8F30427Q37820247-EA854DCD-4A96-4E48-BC3A-908D08A0DC78Q38633596-680FB0CC-767D-485B-A302-6415A6A9B124Q38661997-DFB66A03-584F-4E8C-9F88-C917AE797290Q39393866-773B6A3F-1263-435F-AA52-E50A79CA89B2Q39796268-8C65ED30-BE7D-407B-876C-5BD80FD61947Q40822573-0122CFB7-562A-4D33-A3C4-87B69A8704C6Q40865226-C4249EEC-66F9-46C8-AD5E-19BE9D316A64Q41862260-A8DB889C-0B53-4320-875E-85CAE3374A2AQ44040170-23F5F29E-82E9-4282-ADFC-B3C5C228A140Q46255773-21D3E583-37AD-4F8F-B5DA-FECE9641A628Q51174776-B4BD0488-F6D5-4BE5-9DA0-0334785ADFD7
P2860
Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.
description
1998 nî lūn-bûn
@nan
1998 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.
@ast
Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.
@en
type
label
Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.
@ast
Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.
@en
prefLabel
Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.
@ast
Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.
@en
P2093
P2860
P356
P1476
Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.
@en
P2093
Beuerlein G
Watkins JD
P2860
P304
P356
10.1073/PNAS.95.11.6037
P407
P577
1998-05-01T00:00:00Z